-
21.发明申请公开(公告)号：US20120207670A1
公开(公告)日：2012-08-16
申请号：US13299831
申请日：2011-11-18
Applicant: Jill Giles-Komar , George Heavner , David Knight , Jinquan Luo , David Peritt , Bernard Scallon , David Shealy
Inventor： Jill Giles-Komar , George Heavner , David Knight , Jinquan Luo , David Peritt , Bernard Scallon , David Shealy
IPC: A61K39/395 , A61P29/00 , A61P23/00 , A61P37/00 , A61P37/04 , A61P5/00 , A61P37/06 , A61P23/02 , A61K51/00 , A61P21/00 , A61P21/02 , A61P25/20 , A61P17/06 , A61P31/00
CPC classification number: C07K16/244 , A61K31/137 , A61K31/56 , A61K38/27 , A61K39/3955 , A61K45/06 , A61K51/00 , A61K2039/505 , C07K14/54 , C07K14/5434 , C07K2317/14 , C07K2317/21 , C07K2317/34 , C07K2317/55 , C07K2317/76 , C12Q1/6876
Abstract: An anti-IL-12 antibody that binds to a portion of the IL-12 protein corresponding to at least one amino acid residue selected from the group consisting of residues 15, 17-21, 23, 40-43, 45-47, 54-56 and 58-62 of the amino acid sequence of the p40 subunit of IL-12, including isolated nucleic acids that encode at least one anti-IL-12 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in treating IL-12-related disorders, such as psoriasis.
Abstract translation: 结合IL-12蛋白的一部分对应于至少一个氨基酸残基的抗IL-12抗体，其选自残基15,17-21,23,40-43,45-47,54 -56和58-62的IL-12的p40亚基的氨基酸序列，包括编码至少一种抗IL-12抗体，载体，宿主细胞，转基因动物或植物的分离的核酸，以及制备方法 并且其用途可用于治疗诸如银屑病的IL-12相关疾病。
-
公开(公告)号：US20110082190A1
公开(公告)日：2011-04-07
申请号：US12971626
申请日：2010-12-17
Applicant: Jill Giles-Komar , David M. Knight , David Peritt , Bernard Scallon , David Shealy
Inventor： Jill Giles-Komar , David M. Knight , David Peritt , Bernard Scallon , David Shealy
IPC: A61K31/7088 , C07H21/00 , C12N15/63 , C12N5/10 , C12P21/02 , A61P37/00 , A61P9/00 , A61P31/00 , A61P35/00 , A61P25/00 , C12N1/00
CPC classification number: C07K16/244 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2317/21 , C07K2317/565 , C07K2317/76 , C07K2317/92
Abstract: Isolated anti-IL-12 antibodies, nucleic acids encoding antibodies or antibody portions, vectors, host cells, and methods of making are useful for production of antibody or portions for treating and/or diagnosing IL-12 related conditions, diseases, and disorders.
Abstract translation: 分离的抗IL-12抗体，编码抗体或抗体部分的核酸，载体，宿主细胞和制备方法可用于产生抗体或用于治疗和/或诊断IL-12相关病症和疾病的部分。
-
公开(公告)号：US07820169B2
公开(公告)日：2010-10-26
申请号：US12268955
申请日：2008-11-11
Applicant: George Heavner , David M. Knight , Jill Giles-Komar , Bernard Scallon , David Shealy
Inventor： George Heavner , David M. Knight , Jill Giles-Komar , Bernard Scallon , David Shealy
IPC: A61K39/395 , A61K31/573 , A61K49/00 , C07K16/00
CPC classification number: C07K16/241 , A61K9/19 , A61K38/1816 , A61K38/19 , A61K38/27 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/42 , C07K16/4241 , C07K2317/14 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , G01N33/566 , Y02A50/386 , Y02A50/412 , Y10S514/825 , Y10S514/826
Abstract: The present invention relates to inhibiting TNF in patients having rheumatoid arthritis, psoriatic arthritis or ankylosing spondilitis, by administering anti-TNF antibodies comprising the heavy chain variable region of SEQ ID NO: 7 and the light chain variable region of SEQ ID NO:8, specific for at least one human tumor necrosis factor alpha (TNF) protein or fragment thereof.
-
公开(公告)号：US20090202549A1
公开(公告)日：2009-08-13
申请号：US11722312
申请日：2005-12-20
Applicant: Jill Giles-Komar , George Heavner , David Knight , Jinquan Luo , David Peritt , Bernard Scallon , David Shealy
Inventor： Jill Giles-Komar , George Heavner , David Knight , Jinquan Luo , David Peritt , Bernard Scallon , David Shealy
CPC classification number: C07K16/244 , A61K31/137 , A61K31/56 , A61K38/27 , A61K39/3955 , A61K45/06 , A61K51/00 , A61K2039/505 , C07K14/54 , C07K14/5434 , C07K2317/14 , C07K2317/21 , C07K2317/34 , C07K2317/55 , C07K2317/76 , C12Q1/6876
Abstract: An anti-IL-12 antibody that binds to a portion of the IL-12 protein corresponding to at least one amino acid residue selected from the group consisting of residues 15, 17-21, 23, 40-43, 45-47, 54-56 and 58-62 of the amino acid sequence of the p40 subunit of IL-12, including isolated nucleic acids that encode at least one anti-IL-12 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.
Abstract translation: 结合IL-12蛋白的一部分对应于至少一个氨基酸残基的抗IL-12抗体，其选自残基15,17-21,23,40-43,45-47,54 -56和58-62的IL-12的p40亚基的氨基酸序列，包括编码至少一种抗IL-12抗体，载体，宿主细胞，转基因动物或植物的分离的核酸，以及制备方法 并且其使用在诊断和/或治疗组合物，方法和装置中具有应用。
-
25.发明授权公开(公告)号：US07279157B2
公开(公告)日：2007-10-09
申请号：US10975883
申请日：2004-10-28
Applicant: Jill Giles-Komar , David M. Knight , David Peritt , Bernard Scallon , David Shealy
Inventor： Jill Giles-Komar , David M. Knight , David Peritt , Bernard Scallon , David Shealy
IPC: A61K39/395
CPC classification number: C07K16/244 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2317/21 , C07K2317/565 , C07K2317/76 , C07K2317/92
Abstract: The present invention relates to an anti-IL-12 antibody, including isolated nucleic acids that encode an anti-IL-12 antibody, IL-12, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.
Abstract translation: 本发明涉及抗IL-12抗体，包括编码抗IL-12抗体，IL-12，载体，宿主细胞，转基因动物或植物的分离的核酸及其制备和使用方法，包括 治疗组合物，方法和装置。
-
Patent Agency Ranking
公开(公告)号：US20070196373A1
公开(公告)日：2007-08-23
申请号：US11501162
申请日：2006-08-08
Applicant: Junming Le , Jan Vilcek , Peter Daddona , John Ghrayeb , David Knight , Scott Siegel , David Shealy
Inventor： Junming Le , Jan Vilcek , Peter Daddona , John Ghrayeb , David Knight , Scott Siegel , David Shealy
IPC: A61K39/395
CPC classification number: C07K16/241 , A61K2039/505 , C07K16/30 , C07K2317/24 , C07K2317/34 , C07K2317/76 , C07K2317/92 , C07K2319/00 , Y02A50/412
Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated pathologies and conditions, including ankylosing spondylitis, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.
Abstract translation: 抗TNF抗体，其对人肿瘤坏死因子-α（TNFalpha）特异性的片段和区域，并且可用于许多TNFα介导的病理学和病症（包括强直性脊柱炎）的体内诊断和治疗，以及编码 提供了鼠和嵌合抗体，免疫测定和免疫治疗方法中产生抗体的方法，抗TNF抗体或其片段，区域或衍生物的使用方法。
-
公开(公告)号：US20050214293A1
公开(公告)日：2005-09-29
申请号：US10975708
申请日：2004-10-28
Applicant: Jill Giles-Komar , David Knight , David Peritt , Bernard Scallon , David Shealy
Inventor： Jill Giles-Komar , David Knight , David Peritt , Bernard Scallon , David Shealy
IPC: A01H1/00 , A01K67/027 , A61K20060101 , A61K38/00 , A61K39/395 , A61K45/00 , A61P20060101 , A61P17/06 , A61P25/00 , A61P37/00 , A61P43/00 , C07K20060101 , C07K16/24 , C12N20060101 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/09 , C12N15/13 , C12P21/08 , G01N20060101
CPC classification number: C07K16/244 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2317/21 , C07K2317/565 , C07K2317/76 , C07K2317/92
Abstract: The present invention relates to an anti-IL-12 antibody, including isolated nucleic acids that encode an anti-IL-12 antibody, IL-12, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.
Abstract translation: 本发明涉及抗IL-12抗体，包括编码抗IL-12抗体，IL-12，载体，宿主细胞，转基因动物或植物的分离的核酸及其制备和使用方法，包括 治疗组合物，方法和装置。
-
公开(公告)号：US20050112127A1
公开(公告)日：2005-05-26
申请号：US10975883
申请日：2004-10-28
Applicant: Jill Giles-Komar , David Knight , David Peritt , Bernard Scallon , David Shealy
Inventor： Jill Giles-Komar , David Knight , David Peritt , Bernard Scallon , David Shealy
IPC: A01H1/00 , A01K67/027 , A61K20060101 , A61K38/00 , A61K39/395 , A61K45/00 , A61P20060101 , A61P17/06 , A61P25/00 , A61P37/00 , A61P43/00 , C07K20060101 , C07K16/24 , C12N20060101 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/09 , C12N15/13 , C12P21/08 , G01N20060101
CPC classification number: C07K16/244 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2317/21 , C07K2317/565 , C07K2317/76 , C07K2317/92
Abstract: The present invention relates to an anti-IL-12 antibody, including isolated nucleic acids that encode an anti-IL-12 antibody, IL-12, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.
Abstract translation: 本发明涉及抗IL-12抗体，包括编码抗IL-12抗体，IL-12，载体，宿主细胞，转基因动物或植物的分离的核酸及其制备和使用方法，包括 治疗组合物，方法和装置。
-
公开(公告)号：US20050084491A1
公开(公告)日：2005-04-21
申请号：US10873848
申请日：2004-06-22
Applicant: David Shealy , Sam Wu , Yan Chen , Audrey Baker
Inventor： David Shealy , Sam Wu , Yan Chen , Audrey Baker
IPC: A61K38/04 , A61K39/395 , C07K20060101 , C07K7/06 , C07K7/08 , C07K14/705 , C07K16/28 , C07K16/46 , C12P21/04 , C12Q1/68
CPC classification number: C07K7/06 , C07K14/70557
Abstract: The invention concerns antagonists of alphav-containing integrins which have therapeutic activity in oncology applications and methods for selecting such antagonists using a peptide which competes for alphaV-integrin binding with a known monoclonal antibody having demonstrated anti-tumor activity. The claimed peptide represents a conformational epitope or mimotope present on the ligand to which the therapeutic antibodies selectively bind.
Abstract translation: 本发明涉及在肿瘤学应用中具有治疗活性的α融合整联蛋白的拮抗剂，以及使用与已证实具有抗肿瘤活性的已知单克隆抗体竞争αV-整联蛋白结合的肽来选择此类拮抗剂的方法。 要求保护的肽表示存在于治疗性抗体选择性结合的配体上的构象表位或模拟表位。
-
公开(公告)号：US07887807B2
公开(公告)日：2011-02-15
申请号：US12500120
申请日：2009-07-09
Applicant: Jill Giles-Komar , David M. Knight , David Peritt , Bernard Scallon , David Shealy
Inventor： Jill Giles-Komar , David M. Knight , David Peritt , Bernard Scallon , David Shealy
IPC: C07K16/24 , A61K39/395
CPC classification number: C07K16/244 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2317/21 , C07K2317/565 , C07K2317/76 , C07K2317/92
Abstract: Isolated anti-IL-12 antibodies, nucleic acids encoding antibodies or antibody portions, vectors, host cells, and methods of making are useful for production of antibody or portions for treating and/or diagnosing IL-12 related conditions, diseases, and disorders.
Abstract translation: 分离的抗IL-12抗体，编码抗体或抗体部分的核酸，载体，宿主细胞和制备方法可用于产生抗体或用于治疗和/或诊断IL-12相关病症和疾病的部分。
-
-
-
-
-
-
-
-
-
Search Results
48
records
(took 0.034 seconds)
